On September 2, 2026, ACRO BIOMEDICAL appointed Shao-Hsiang Shih chairman and Jing-Zhou Chen chief executive and chief financial officer, while Yu-Ting Su resigned her Leadership posts. Investors now have identified successors for the board chair, CEO and CFO roles, with the appointments effective on the same date.
Key Highlights
- Yu-Ting Su’s resignation was not linked to any disagreement with ACRO BIOMEDICAL.
- Shao-Hsiang Shih has held an administrative management leadership role at Century Publishing since 2020.
- Jing-Zhou Chen founded Dream Born and has led the company since 2025.
New Chairman and Combined Executive Roles
Before Dream Born, Chen led GBT Cloud Kitchen and Hongxi Enterprise Management from 2020 to 2025. He also co-founded POKE25, held an operations role at G-Store Smart Retail Technology, and worked in semiconductor process and equipment engineering at Genes Tech and STATS ChipPAC Taiwan from 2011 to 2016. Chen holds an electrical-engineering bachelor’s degree from National United University and is enrolled in an executive MBA program at National Taipei University of Technology.
FAQs
Q: Who is the new chairman of ACRO BIOMEDICAL?
A: Shao-Hsiang Shih became ACRO BIOMEDICAL’s chairman and a director on September 2, 2026. His professional background includes administrative and education management roles at Century Publishing.
Q: Who is ACRO BIOMEDICAL’s new CEO and CFO?
A: Jing-Zhou Chen was appointed ACRO BIOMEDICAL’s chief executive officer and chief financial officer effective September 2, 2026. He has served as founder and CEO of Dream Born Co. Ltd. since March 2025.
Q: Why did Yu-Ting Su leave ACRO BIOMEDICAL?
A: Yu-Ting Su resigned as ACRO BIOMEDICAL’s director, chairman and chief executive officer. The resignation was not related to any disagreement with the company.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.